TEVA-LIOTHYRONINE TABLET

Χώρα: Καναδάς

Γλώσσα: Αγγλικά

Πηγή: Health Canada

Δραστική ουσία:

LIOTHYRONINE (LIOTHYRONINE SODIUM)

Διαθέσιμο από:

TEVA CANADA LIMITED

Φαρμακολογική κατηγορία (ATC):

H03AA02

INN (Διεθνής Όνομα):

LIOTHYRONINE SODIUM

Δοσολογία:

25MCG

Φαρμακοτεχνική μορφή:

TABLET

Σύνθεση:

LIOTHYRONINE (LIOTHYRONINE SODIUM) 25MCG

Οδός χορήγησης:

ORAL

Μονάδες σε πακέτο:

15G/50G

Τρόπος διάθεσης:

Prescription

Θεραπευτική περιοχή:

THYROID AGENTS

Περίληψη προϊόντος:

Active ingredient group (AIG) number: 0102421002; AHFS:

Καθεστώς αδειοδότησης:

APPROVED

Ημερομηνία της άδειας:

2019-11-21

Αρχείο Π.Χ.Π.

_ _
_Teva-Liothyronine Tablets _
_Page 1 of 17_
PRODUCT MONOGRAPH
Pr
TEVA-LIOTHYRONINE
Liothyronine Sodium Tablets
5 mcg and 25 mcg liothyronine as liothyronine sodium
USP
Hypothyroidism Therapy
Teva Canada Limited
30 Novopharm Court
Toronto, Ontario
M1B 2K9
Date of Approval:
November 20, 2019
Submission Control No: 217318
_ _
_Teva-Liothyronine Tablets _
_Page 2 of 17_
TABLE OF CONTENTS
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................6
DRUG INTERACTIONS
....................................................................................................7
DRUG/LABORATORY TEST INTERACTIONS
.............................................................9
DOSAGE AND ADMINISTRATION
..............................................................................10
OVERDOSAGE
................................................................................................................11
ACTION
............................................................................................................................12
CLINICAL PHARMACOLOGY
......................................................................................12
SUPPLY
.............................................................................................................................15
COMPOSITION
................................................................................................................15
PART III: CONSUMER INFORMATION
......................................................................16
_ _
_Teva-Liothyronine Tablets _
_Page 3 of 17_
Pr
TEVA-LIOTHYRONINE
liothyronine sodium
INDICATIONS AND CLINICAL USE
TEVA-LIOTHYRONINE is